ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: FDA Opens Advisory Committee Consideration Of NDAs, Finds Discussion Is Not Inhibited

September 10, 1976

FDA Requires Independent Confirmation of Disease Progression in Cooperative Group Trials; Seeks Documentation for Avastin in Breast Cancer.

September 15, 2006

Cooperative Groups: Committee Formed To Implement Armitage Report Had A Rough Start

June 12, 1998

DeVita Accepts “Chop Lie” Cancer Control Elements In CCOP; RFA Delays Until After May NCAB Meeting

March 12, 1982

Ethics Commission To Continue Consideration Of Compensation For Injured Research Subjects

June 20, 1980

In Brief: Marasco New ACR President, Barbara Chick VP; Wolmark Named Surgeon In Chief Of Montefiore

October 10, 1986